<DOC>
	<DOC>NCT02147431</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the effect of semaglutide on hypoglycaemic counter-regulation compared to placebo in subjects with type 2 diabetes.</brief_summary>
	<brief_title>A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Subjects diagnosed with type 2 diabetes and on stable treatment for a period of 90 days prior to screening with metformin as monotherapy. Stable is defined as unchanged dose Male or female, age between1864 years (both inclusive) at the time of signing informed consent Body Mass Index (BMI) between 20.035.0 kg/m^2 (both inclusive) HbA1c (glycosylated haemoglobin) between 6.510.0% (both inclusive) Treatment with any glucose lowering agent(s) other than metformin in a period of 90 days before screening. An exception is shortterm treatment (less than or equal to 7 days in total) with insulin in connection with intercurrent illness Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months Blood or plasma donation within the past month or more than 500 mL within the last 3 months prior to first semaglutide dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>